Abstract 5636: Identification of bladder cancer-associated cancer-testis antigens-derived long peptides encompassing both CTL and promiscuous HLA class II-restricted Th cell epitopes

2018 ◽  
Author(s):  
Yasuharu Nishimura ◽  
Miki Tsuruta ◽  
Shohei Ueda ◽  
Poh Yin Yew ◽  
Isao Fukuda ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Class Ii ◽  
Hla Class Ii ◽  
Cancer Testis Antigens ◽  
Th Cell ◽  
Cancer Testis

scholarly journals Co-expression of cancer-testis antigens of MAGE-A6 and MAGE-A11 is associated with tumor aggressiveness in patients with bladder cancer

2022 ◽  
Vol 12 (1) ◽  
Author(s):  
Monireh Mohsenzadegan ◽  
Mahdieh Razmi ◽  
Somayeh Vafaei ◽  
Maryam Abolhasani ◽  
Zahra Madjd ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Histological Grade ◽  
Immunohistochemical Analysis ◽  
Tumor Aggressiveness ◽  
P Values ◽  
Normal Tissues ◽  
Cancer Testis Antigens ◽  
Clinicopathological Significance ◽  
The Common ◽  
Cancer Testis

AbstractMelanoma antigen gene (MAGE)-A6 and MAGE-A11 are two of the most cancer-testis antigens overexpressed in various types of cancers. However, the clinical and prognosis value of MAGE-A6 and MAGE-A11 co-expression in the pathophysiology of the bladder is unknown. Three studies were selected from GEO databases in order to introduce the common genes that are involved in bladder cancer. Then immunohistochemical analysis for staining pattern and clinicopathological significance of suggested markers, MAGE-A6 and MAGE-A11, were performed in 199 and 213 paraffin-embedded bladder cancer with long adjacent normal tissues, respectively. A significant and positive correlation was found between both nuclear and cytoplasmic expressions of MAGE-A6 as well as expression of cytoplasmic MAGE-A11 with histological grade, PT stage, lamina propria invasion, and LP/ muscularis (L/M) involvement (all of the p-values in terms of H-score were < 0.0001). Additionally, significant differences were found between both nuclear and cytoplasmic MAGE-A6/MAGE-A11 phenotypes with tumor size (P = 0.007, P = 0.043, respectively), different histological grades, PT stage, LP involvement, and L/M involvement (all of the p-values for both phenotypes were < 0.0001). The current study added the value of these novel markers to the bladder cancer clinical settlement that might be considered as an admirable target for immunotherapy.

Expression analysis of a panel of cancer-testis antigens in bladder cancer

2018 ◽  
Vol 15 (6) ◽  
pp. 511-520 ◽  
Author(s):  
Fatemeh Yazarlou ◽  
Vahid Kholghi-Oskooei ◽  
Mandana Afsharpad ◽  
Leila Nekoohesh ◽  
Tamouchin Moharrami ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Expression Analysis ◽  
Cancer Testis Antigens ◽  
Cancer Testis

MHC and malaria: the relationship between HLA class II alleles and immune responses to Plasmodium falciprum

1992 ◽  
Vol 4 (9) ◽  
pp. 1055-1063 ◽  
Author(s):  
E. M. Riley ◽  
O. Olerup ◽  
S. Bennett ◽  
P. Rowe ◽  
S. J. Allen ◽  
...  
Keyword(s):  
Immune Responses ◽  
Class Ii ◽  
Hla Class Ii ◽  
The Relationship ◽  
Hla Class Ii Alleles

scholarly journals Expression of Cancer Testis Antigens in Tumor-Adjacent Normal Liver Is Associated with Post-Resection Recurrence of Hepatocellular Carcinoma

Cancers ◽  
2021 ◽  
Vol 13 (10) ◽  
pp. 2499
Author(s):  
Lisanne Noordam ◽  
Zhouhong Ge ◽  
Hadiye Özturk ◽  
Michail Doukas ◽  
Shanta Mancham ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Normal Liver ◽  
Occult Metastasis ◽  
Recurrence Rates ◽  
Curative Intent ◽  
Cancer Testis Antigens ◽  
Negative Prognostic Factor ◽  
Increased Risk ◽  
Hcc Recurrence ◽  
Cancer Testis

High recurrence rates after resection of hepatocellular carcinoma (HCC) with curative intent impair clinical outcomes of HCC. Cancer/testis antigens (CTAs) are suitable targets for cancer immunotherapy if selectively expressed in tumor cells. The aims were to identify CTAs that are frequently and selectively expressed in HCC-tumors, and to investigate whether CTAs could serve as biomarkers for occult metastasis. Tumor and paired tumor-free liver (TFL) tissues of HCC-patients and healthy tissues were assessed for mRNA expression of 49 CTAs by RT-qPCR and protein expression of five CTAs by immunohistochemistry. Twelve CTA-mRNAs were expressed in ≥10% of HCC-tumors and not in healthy tissues except testis. In tumors, mRNA and protein of ≥ 1 CTA was expressed in 78% and 71% of HCC-patients, respectively. In TFL, CTA mRNA and protein was found in 45% and 30% of HCC-patients, respectively. Interestingly, CTA-expression in TFL was an independent negative prognostic factor for post-resection HCC-recurrence and survival. We established a panel of 12 testis-restricted CTAs expressed in tumors of most HCC-patients. The increased risk of HCC-recurrence in patients with CTA expression in TFL, suggests that CTA-expressing (pre-)malignant cells may be a source of HCC-recurrence, reflecting the relevance of targeting these to prevent HCC-recurrence.

Sign in / Sign up

Export Citation Format

Share Document